384 related articles for article (PubMed ID: 37240224)
21. Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation.
Chantharasamee J; Poungvarin N; Danchaivijitr P; Techawatanawanna S
BMC Cancer; 2019 Jul; 19(1):701. PubMed ID: 31315599
[TBL] [Abstract][Full Text] [Related]
22. Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG).
Popat S; Hsia TC; Hung JY; Jung HA; Shih JY; Park CK; Lee SH; Okamoto T; Ahn HK; Lee YC; Sato Y; Lee SS; Mascaux C; Daoud H; Märten A; Miura S
Oncologist; 2022 Apr; 27(4):255-265. PubMed ID: 35274704
[TBL] [Abstract][Full Text] [Related]
23. Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.
Wu JY; Yu CJ; Chang YC; Yang CH; Shih JY; Yang PC
Clin Cancer Res; 2011 Jun; 17(11):3812-21. PubMed ID: 21531810
[TBL] [Abstract][Full Text] [Related]
24. Chemotherapy outcomes in EGFR-TKI resistant patients with common and uncommon EGFR mutation: An exploratory retrospective cohort study.
Lin CY; Hu CH; Hsu CF; Tsai JS; Chen CW; Lin CY; Chang CC; Yen YT; Tseng YL; Su PL; Lin CC
Thorac Cancer; 2023 Jul; 14(19):1857-1864. PubMed ID: 37183851
[TBL] [Abstract][Full Text] [Related]
25. [A Review of EGFR-TKIs Therapy of Non-small Cell Lung Cancer
with Uncommon EGFR Mutations].
Du W; Wo Y; Lu T; Wang Y; Jiao W
Zhongguo Fei Ai Za Zhi; 2019 Sep; 22(9):590-599. PubMed ID: 31526464
[TBL] [Abstract][Full Text] [Related]
26. Compound EGFR mutations and response to EGFR tyrosine kinase inhibitors.
Kobayashi S; Canepa HM; Bailey AS; Nakayama S; Yamaguchi N; Goldstein MA; Huberman MS; Costa DB
J Thorac Oncol; 2013 Jan; 8(1):45-51. PubMed ID: 23242437
[TBL] [Abstract][Full Text] [Related]
27. Uncommon single and compound EGFR mutations: clinical outcomes of a heterogeneous subgroup of NSCLC.
Rossi S; Damiano P; Toschi L; Finocchiaro G; Giordano L; Marinello A; Bria E; D'Argento E; Santoro A
Curr Probl Cancer; 2022 Feb; 46(1):100787. PubMed ID: 34489119
[TBL] [Abstract][Full Text] [Related]
28. Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer harboring uncommon EGFR mutations: Real-world data from Taiwan.
Chang JW; Huang CY; Fang YF; Chang CF; Yang CT; Kuo CS; Hsu PC; Wu CE
Thorac Cancer; 2023 Jan; 14(1):12-23. PubMed ID: 36424878
[TBL] [Abstract][Full Text] [Related]
29. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
30. Rare mutations of epidermal growth factor receptor in epidermal growth factor receptor-tyrosine kinase inhibitor-naive non-small cell lung carcinoma and the response to erlotinib therapy.
Sari M; Aydiner A
J Cancer Res Ther; 2020; 16(1):132-138. PubMed ID: 32362623
[TBL] [Abstract][Full Text] [Related]
31. [Effectiveness of Tyrosine Kinase Inhibitors on Uncommon Epidermal Growth Factor
Receptor Mutations in Non-small Cell Lung Cancer].
Yang X; Chen H; Zhang H; Duan J; An T; Zhao J; Zhuo M; Wu M; Wang J
Zhongguo Fei Ai Za Zhi; 2015 Aug; 18(8):493-9. PubMed ID: 26302346
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness of Treatments for Advanced Non-Small-Cell Lung Cancer With Exon 20 Insertion Epidermal Growth Factor Receptor Mutations.
Wu JY; Yu CJ; Shih JY
Clin Lung Cancer; 2019 Nov; 20(6):e620-e630. PubMed ID: 31327643
[TBL] [Abstract][Full Text] [Related]
33. Rare epidermal growth factor receptor gene alterations in non-small cell lung cancer patients, tyrosine kinase inhibitor response and outcome analysis.
Mehta A; Vasudevan S
Cancer Treat Res Commun; 2021; 28():100398. PubMed ID: 34052672
[TBL] [Abstract][Full Text] [Related]
34. Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor?
Banno E; Togashi Y; Nakamura Y; Chiba M; Kobayashi Y; Hayashi H; Terashima M; de Velasco MA; Sakai K; Fujita Y; Mitsudomi T; Nishio K
Cancer Sci; 2016 Aug; 107(8):1134-40. PubMed ID: 27240419
[TBL] [Abstract][Full Text] [Related]
35. EGFR exon20 insertion mutations in non-small cell lung cancer: Clinical implications and recent advances in targeted therapies.
Bai Q; Wang J; Zhou X
Cancer Treat Rev; 2023 Nov; 120():102605. PubMed ID: 37703723
[TBL] [Abstract][Full Text] [Related]
36. Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in
Hirano T; Yasuda H; Hamamoto J; Nukaga S; Masuzawa K; Kawada I; Naoki K; Niimi T; Mimasu S; Sakagami H; Soejima K; Betsuyaku T
Mol Cancer Ther; 2018 Apr; 17(4):740-750. PubMed ID: 29467275
[TBL] [Abstract][Full Text] [Related]
37. Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs).
Martínez-Navarro EM; Rebollo J; González-Manzano R; Sureda M; Evgenyeva E; Valenzuela B; Fernández FJ; Forteza J; Brugarolas A
Clin Transl Oncol; 2011 Nov; 13(11):812-8. PubMed ID: 22082647
[TBL] [Abstract][Full Text] [Related]
38. A non-small cell lung cancer (NSCLC) patient harboring a rare epidermal growth factor receptor (EGFR) L858R/V843I mutation complex benefited from osimertinib: a case report.
Zhou Y; Qi X; Wang Y; Dong H; Zhuang L
Ann Palliat Med; 2022 Mar; 11(3):1121-1125. PubMed ID: 35365042
[TBL] [Abstract][Full Text] [Related]
39. Uncommon frame-shift exon 19 EGFR mutations are sensitive to EGFR tyrosine kinase inhibitors in non-small cell lung carcinoma.
Improta G; Zupa A; Natalicchio MI; Sisinni L; Marinaccio A; Bozza G; Vita G; Aieta M; Landriscina M
Med Oncol; 2018 Jan; 35(3):28. PubMed ID: 29387949
[TBL] [Abstract][Full Text] [Related]
40. Current management of uncommon EGFR mutations in non-small cell lung cancer.
Trinh JQ; Abughanimeh O
Curr Probl Cancer; 2024 Apr; 49():101064. PubMed ID: 38311523
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
